NCT06114082 (IDADOX) is a Phase 2 clinical trial of IDA-TACE in Hepatocellular Carcinoma, sponsored by Seoul National University Hospital.

Who is sponsoring NCT06114082?

NCT06114082 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT06114082?

Interventions in NCT06114082: IDA-TACE, DOX-TACE.

What condition does NCT06114082 study?

NCT06114082 studies Hepatocellular Carcinoma, Liver Cancer.

Is NCT06114082 still recruiting?

NCT06114082 is currently recruiting now. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT06114082: IDADOX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

Recruiting now Phase 2 Last updated 7 January 2025

What this trial tests

Phase 2 trial testing IDA-TACE in Hepatocellular Carcinoma in 128 participants. Currently enrolling.

Timeline

28 April 2023

Primary endpoint
31 December 2025

30 June 2026

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	128
Start date	28 April 2023
Primary completion	31 December 2025
Estimated completion	30 June 2026
Sites	1 location across South Korea

Drugs / interventions tested

IDA-TACE
DOX-TACE

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Liver Cancer — all drugs for Liver Cancer →

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Hepatocellular Carcinoma or Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma. Although doxorubicin is the most commonly-used chemotherapeutic agent in the world, idarubicin is recently in the spotlight after promising results of the in vitro and prospective single-arm studies. On the other hand, there are many reports showing that the type of chemotherapeutic agents does not significantly alter the efficacy of transarterial chemoembolization. This is a randomized-controlled trial to show the non-inferiority of idarubicin compared to doxorubicin in patients with hepatocellular carcinoma who receive transarterial chemoembolization as the first-line treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial.
Choi JW, Kim HC, Han J, Jang MJ, et al · · 2024 · cited 2× · PMID 38147153 · DOI 10.1007/s00270-023-03621-9

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06114082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing